Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc. (OCUL), sold 3,063 shares of the company's common stock on 08/25/2025 at a weighted average price of $12.04 per share. The sale was executed under a durable automatic sale instruction adopted April 9, 2024, as a sell-to-cover to satisfy tax withholding tied to restricted stock units that vested on 08/22/2025. Following the reported transactions, Heier beneficially owned 259,911 shares. The filing notes the sales were not discretionary and were executed across prices ranging from $11.89 to $12.16.
Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc. (OCUL), reported the sale of 21,494 shares of the company's common stock on 08/25/2025 under a pre-established durable automatic sale instruction intended to satisfy tax withholding for restricted stock units that vested on 08/22/2025. The shares were sold at a weighted average price of $12.04, with transaction prices ranging from $11.89 to $12.18. After the sale, the reporting person beneficially owned 3,227,244 shares directly and 250,361 shares indirectly through the Pravin Dugel 2024 Irrevocable Trust. The filing was signed by an attorney-in-fact on behalf of Mr. Dugel on 08/27/2025.
Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 21,494 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $258,757.67. The filing shows 173,995,221 shares outstanding and an approximate sale date of 08/25/2025. The shares were acquired on 08/22/2025 by restricted stock vesting under a registered plan and payment/transfer is recorded as 08/22/2025.
The filer certifies no undisclosed material adverse information. No other sales in the past three months are reported. This is a routine notice of proposed sale under Rule 144 showing a short waiting period between vesting and the planned sale.
Ocular Therapeutix (OCUL) filed a Form 144 reporting an intended sale of 1,885 common shares through Morgan Stanley Smith Barney LLC on 08/25/2025 on NASDAQ with an aggregate market value of $22,701.62. The shares were acquired on 08/22/2025 as restricted stock vesting under a registered plan and were received as compensation. The filer reports no securities sold by the same person in the past three months and affirms no undisclosed material adverse information.
Ocular Therapeutix filed a Form 144 notifying of a proposed sale of 3,063 shares of its common stock that were acquired through restricted stock vesting on 08/22/2025. The filing lists the intended sale date as 08/25/2025, an aggregate market value of $36,882.81, and indicates the shares trade on NASDAQ. The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
The filer represents no material nonpublic information is known and notes no sales by the person in the past three months. Certain identifying fields (for example, filer CIK and filer name) are not populated in the provided content.
Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 3,011 shares of common stock with an aggregate market value of $36,252.74. The shares represent a very small portion of the company’s reported 173,995,221 outstanding shares and are listed for sale on NASDAQ with an approximate sale date of 08/25/2025.
The filing notes the shares were acquired on 08/22/2025 from restricted stock vesting under a registered plan and that no securities of the issuer were sold by the reporting person in the past three months. The filer certifies there is no undisclosed material adverse information about the issuer in connection with this notice.
Ocular Therapeutix insider grant summary: Nadia Waheed, the companys Chief Medical Officer, received equity awards on 08/12/2025. She was granted 40,363 restricted stock units (RSUs), each representing a right to one share, which vest over three years in equal annual installments beginning February 11, 2026. She also received a stock option to purchase 122,923 shares at an exercise price of $12.48 per share; the option vests partially (7/48) on September 11, 2025, with the remainder vesting monthly through February 11, 2029, and expires August 11, 2035. Following these transactions, Waheed reports beneficial ownership of 247,168 shares and 122,923 underlying option shares.
Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix (OCUL), reported a series of gift transfers of common stock among family-related parties and an irrevocable trust. On April 28, 2025 he transferred 200,332 shares to his spouse for no consideration and on June 12, 2025 he transferred 50,029 shares to his spouse for no consideration. On August 11, 2025 the spouse transferred 250,361 shares to the "Pravin Dugel 2024 Irrevocable Trust" for no consideration.
The filing states Mr. Dugel is the trustee and sole beneficiary of the Trust during his lifetime and "remains the beneficial owner of the securities held by the Trust." Reported direct beneficial ownership after the June transfer is 3,248,738 shares, and the Trust holds 250,361 shares indirectly.